PIRAMAL Healthcare Limited has
announced it has entered into an
agreement with Bayer Pharma to
acquire worldwide rights to the
latter’s molecular imaging research
and development portfolio.
The portfolio includes rights to
florbetaben, which is in the final
stages of its Phase III clinical trials.
“We plan to build a promising
portfolio in the pharma space,
including our newly acquired
Molecular Imaging assets, which
will help us create a global branded
pharma business,” said Ajay
Piramal, Chairman of Piramal
Group.The above article was sent to subscribers in Pharmacy Daily's issue from 16 Apr 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Apr 12
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.